Attana and Linnaeus University commence the second phase of testing with Region Kalmar

Attana has received ~300 post-vaccination patient blood samples from Region Kalmar to be analyzed using Attana’s Diagnostic immunoassay. The samples have been delivered to the lab at the Linnaeus University and will, among other things, be tested for different variants of the SARS-CoV-2 virus and the results will be published in a scientific paper. The study is not only expected to generate interesting results but will also further validate Attana’s unique technology applied in advanced diagnostics.

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: